{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.055","value":"-5.44"},{"groupId":"OG001","spread":"11.959","value":"-2.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Change at Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.488","value":"-14.60"},{"groupId":"OG001","spread":"9.755","value":"-6.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"title":"Change at Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.770","value":"-17.59"},{"groupId":"OG001","spread":"9.758","value":"-5.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Change at Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.882","value":"-21.73"},{"groupId":"OG001","spread":"16.769","value":"-7.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Change at Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.722","value":"-22.47"},{"groupId":"OG001","spread":"21.752","value":"-3.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Change at Cycle 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.555","value":"-23.37"},{"groupId":"OG001","spread":"17.704","value":"-5.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Cycle 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.980","value":"-19.72"},{"groupId":"OG001","spread":"22.463","value":"-7.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Change at Cycle 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.911","value":"-19.35"},{"groupId":"OG001","spread":"10.308","value":"0.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Change at Cycle 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.281","value":"-16.26"},{"groupId":"OG001","spread":"18.973","value":"-0.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Change at End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.704","value":"-1.07"},{"groupId":"OG001","spread":"21.629","value":"-9.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Change at 3-6 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.800","value":"-8.04"},{"groupId":"OG001","spread":"17.789","value":"-9.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Change at 6-9 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.582","value":"-7.94"},{"groupId":"OG001","spread":"14.516","value":"-4.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Change at 9-12 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.438","value":"-16.21"},{"groupId":"OG001","spread":"18.183","value":"-11.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Change at 12-15 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.475","value":"-19.18"},{"groupId":"OG001","spread":"12.768","value":"-8.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Change at 15-18 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.962","value":"-19.27"},{"groupId":"OG001","spread":"16.679","value":"-5.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Change at 18-21 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.875","value":"-16.60"},{"groupId":"OG001","spread":"14.991","value":"-6.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Change at 21-24 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.982","value":"-17.04"},{"groupId":"OG001","spread":"23.990","value":"-9.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Change at 24-27 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.639","value":"-12.45"},{"groupId":"OG001","spread":"16.401","value":"-7.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Change at 27-30 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.470","value":"-11.49"},{"groupId":"OG001","spread":"18.886","value":"-1.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"Change at >30 months LTFU"}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"description":"Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"OG000","title":"Brentuximab Vedotin"},{"description":"Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m\\^2, tablets, orally, once daily with meals for up to 48 weeks.","id":"OG001","title":"Methotrexate or Bexarotene"}],"paramType":"MEAN","populationDescription":"The ITT population included all participants who were identified as CD30+ by the Ventana anti-CD30 (Ber-H2) assay and were randomized to treatment. Here 'Number analyzed' is the number of participants with evaluable data at the specified time-point.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at End of Treatment (EOT) and during posttreatment long treatment follow-up (LTFU) - (Median follow-up 38.8 months)","title":"Change From Baseline in the Skindex-29 Questionnaire Total Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}